Sai Life Sciences announced strong financial results, with revenue up by 43% and EBITDA up by 79% for the nine months ended December 2025. Net profit saw an impressive increase of 199%. The company continues to invest in technology and infrastructure to support future growth and strengthen its position as a leading CRDMO.
Financial Highlights
Sai Life Sciences reported significant growth for the third quarter and nine months ended December 31, 2025.
Q3FY26 Performance (Oct-Dec)
Revenue from Operations reached ₹556 Cr, a 27% increase compared to ₹440 Cr in Q3FY25. EBITDA stood at ₹191 Cr, reflecting a 54% increase from ₹124 Cr in Q3FY25. The company’s Profit After Tax (PAT) significantly improved to ₹100 Cr, an 86% increase compared to ₹54 Cr in the previous year.
9MFY26 Performance (Apr-Dec)
For the nine-month period, Revenue from Operations was ₹1,590 Cr, a 43% increase from ₹1,115 Cr in 9MFY25. EBITDA grew to ₹472 Cr, a substantial 79% increase from ₹264 Cr. PAT soared to ₹245 Cr, a 199% increase from ₹82 Cr in the same period last year.
Business Initiatives
Sai Life Sciences has been actively investing in advanced technologies and infrastructure:
- AI & Digital Platforms: Applied AI-driven retrosynthetic analysis and delivered a library of AI-designed macrocyclic peptides.
- Technology Adoption: Created a centralized group for Photochemistry and Electrochemistry.
- Automation: Implemented automated permeability measurement platform.
Strategic Investments
The company has invested ₹405 Cr in capital expenditure to expand capabilities, part of a planned ₹700 Cr investment for FY26. Sai Life Sciences also emphasizes quality, completing 8 customer audits with zero critical observations, and released its 6th Sustainability Report.
Leadership Commentary
Mr. Krishna Kanumuri, Managing Director and CEO, stated that the company has strengthened its technology platforms and is better equipped to support complex programs. Mr. Siva Chittor, Chief Financial Officer, highlighted the robust revenue growth and margin expansion, supported by disciplined execution and healthy momentum across businesses.
Source: BSE
